Lacktman, Ferrante Comment on Effort to Loosen Telemedicine Restrictions for Prescribing
January 14, 2019
mHealthIntelligence
Partner Nate Lacktman and Senior Counsel TJ Ferrante were quoted in an mHealthIntelligence article, “ATA Presses DEA to Loosen Telemedicine Restrictions for Prescribing,” about a letter from the American Telemedicine Association urging federal authorities to loosen the reins on regulations that restrict mental health professionals from prescribing controlled substances via telehealth.
A blog post by the pair, who worked with the ATA on its recommendations, said the SUPPORT for Patients and Communities Act, which is designed to tackle the nation’s ongoing opioid abuse epidemic, was changed prior to passage to specifically require the U.S. Drug Enforcement Administration to gather public comments – thus enabling the ATA and others to make their opinions heard.
“The recommendations are designed to strike a balance between the country’s great need for additional behavioral health resources, commonly accepted clinical practices, the evolving landscape of telemedicine technologies, and DEA’s charge to protect the safety and wellbeing of citizens via drug diversion,” he wrote.
A blog post by the pair, who worked with the ATA on its recommendations, said the SUPPORT for Patients and Communities Act, which is designed to tackle the nation’s ongoing opioid abuse epidemic, was changed prior to passage to specifically require the U.S. Drug Enforcement Administration to gather public comments – thus enabling the ATA and others to make their opinions heard.
“The recommendations are designed to strike a balance between the country’s great need for additional behavioral health resources, commonly accepted clinical practices, the evolving landscape of telemedicine technologies, and DEA’s charge to protect the safety and wellbeing of citizens via drug diversion,” he wrote.
Related News
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."
July 18, 2025
In the News
Aaron Maguregui Highlights Potential Compliance Concerns in Pre-Tax Wellness Claims
Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.